{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"73"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"345"},{"groupId":"OG001","value":"349"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Stable, Does not qualify for CR, PR, Progression or Symptomatic Deterioration. Clinical Benefit = CR + PR + Stable \\>= 24 weeks","groups":[{"description":"Patients receive oral anastrozole once daily on days 1-28.\n\nanastrozole: Given orally","id":"OG000","title":"Arm I Anastrozole"},{"description":"Patients receive oral anastrozole as in arm I. Patients also receive fulvestrant intramuscularly on days 1, 14, and 28 during course 1 and then on day 28 of the subsequent courses.\n\nanastrozole: Given orally\n\nfulvestrant: Given intramuscularly","id":"OG001","title":"Arm II Anastrozole and Fulvestrant"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Every 4 weeks while on treatment. Then every 3 months until progression, then six months for two years then annually until four years or until death, which ever occurs first.","title":"Clinical Benefit (CR, PR, Confirmed or Unconfirmed, or Stable Disease >= 24 Weeks).","type":"SECONDARY","unitOfMeasure":"percentage of participants"}